Discovery and validation of acetyl-L-carnitine in serum for diagnosis of major depressive disorder and remission status through metabolomic approach.
Level 4 - case-series / case-control
Case-control diagnostic biomarker discovery and validation study
PubMed 36458116 · doi:10.3389/fpsyt.2022.1002828
What was done
Serum metabolites were profiled using mass spectrometry in a discovery set of patients with major depressive disorder (MDD)—including individuals exposed and unexposed to antidepressant treatment—and healthy controls. Candidate biomarkers were evaluated in a separate validation set that included an MDD remission cohort to assess utility for diagnosing MDD and differentiating active depression from remission.
What was found
The abstract reports no numerical values, concentrations, diagnostic accuracy statistics (such as sensitivity, specificity, or AUC), or exact p-values. It reports that metabolomic profiling identified differential metabolites, from which acetylcarnitine (acetyl-L-carnitine) was selected. In validation testing, acetylcarnitine was significantly decreased in MDD patients and distinguished active MDD from remission status, regardless of antidepressant exposure.
Why it matters
Objective blood-based biomarkers for major depressive disorder are lacking. These findings suggest serum acetyl-L-carnitine may serve as a potential marker to assist in MDD diagnosis and remission monitoring independent of antidepressant treatment.
Limits
The abstract omits sample size, participant demographics, effect sizes, and diagnostic test performance metrics. The case-control design cannot establish causality, prospective screening utility in primary care, or specificity against other psychiatric disorders.
Cited by
- supports Acetyl-L-carnitine is low in patients with depression and increases or resolves in association with antidepressant treatment response.